It also induced hepatocyte growth factor (HGF)/MET to drive AKT/mechanistic target of rapamycin kinase (mTOR) signaling pathway and heighten the sensitivity of HCC cells to sorafenib [8]. The gene discussed is AKT1; the disease is hepatocellular carcinoma.